Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(890)
•••
Post by canadafanon Oct 25, 2022 3:09pm
235 Views
Post# 35047658

These are not small potato connections.

These are not small potato connections.

KOL Webinar on Pancreatic Cancer and Interim Results from the Phase 1/2 GOBLET Study Being Presented at the SITC 37th Annual Meeting

 

Monday, November 14, 2022 | 10:00 AM ET

 

Hosted by Oncolytics Biotech Inc 

(NASDAQ: ONCY, TSX: ONC)

Join us for a virtual key opinion leader (KOL) event with Oncolytics Biotech, featuring Dirk Arnold, MD, PhD (Asklepios Tumorzentrum Hamburg), Andrea Bullock, MD, MPH (Beth Israel Deaconess Medical Center) and Thomas Seufferlein, MD, PhD (Ulm University, Germany).

 

During the event, the KOLs and members of the Oncolytics management team will discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as interim results from the Phase 1/2 GOBLET study’s pancreatic cancer cohort being presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

 

A live question and answer session will follow the formal presentations.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities